Sha Di

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sha Di

What is Sha Di?

Sha Di, also known by the botanical name Glehnia littoralis or Glehnia root, is a perennial herb belonging to the Apiaceae family. It is native to the coastal regions of East Asia, including China, Japan, Korea, and parts of the Russian Far East. The plant is characterized by its ability to thrive in sandy environments, such as beach dunes and coastal cliffs, which is reflected in its common names.

Origins and Botanical Description

The medicinal portion of the plant is the long, cylindrical taproot. These roots are typically harvested in the summer or autumn, cleaned, and processed for use. In its raw form, the root has a yellowish-white exterior and a firm, brittle texture. When prepared for use, it is often sliced into thin cross-sections.

Common Uses

In traditional herbal practices, Sha Di is classified for its hydrating properties. It is frequently utilized in various preparations aimed at addressing dryness within the body. Its application is often categorized into several key areas:

  • Respiratory Support: It is often used in contexts where there is a perceived need to moisten the lungs, particularly for persistent dry coughs or a dry throat.
  • Hydration: The herb is associated with the promotion of fluid production, making it a common choice for addressing symptoms of thirst or general dehydration.
  • Digestive Balance: It is sometimes used to support the digestive system, specifically when dryness is thought to be affecting stomach function.

Characteristics

Within the framework of herbal theory, Sha Di is described as having a sweet and slightly bitter flavor profile. It is considered to have a cooling temperature property, which is why it is often selected for conditions characterized by heat and dryness. It is frequently compared to other roots, such as Xi Yang Shen (American Ginseng) or Mai Men Dong (Ophiopogon), due to its similar focus on fluid preservation, though it is often noted for its gentler action.

What side effects are possible with Sha Di?

Possible Side Effects and Safety Information: Sha Di

Official regulatory documents from agencies such as the FDA, EMA, and Health Canada structure the safety profile of a medicine by categorizing and communicating documented adverse reactions. This standardized approach is used to organize the full scope of risks associated with a product.

Since no specific, officially documented adverse reaction profile for a medicine explicitly named "Sha Di" is currently available in these primary government regulatory databases, the safety information is presented based on the required regulatory framework for medicinal products.

Regulatory Safety Structure

Safety Classification Regulatory Requirement Documentation Status for Sha Di
Adverse Reactions Events classified by frequency (Very Common, Common, Rare). Not Officially Documented
System-Organ Classes Events grouped by the affected body system (e.g., Nervous System, Gastrointestinal). Not Officially Documented
Serious Reactions Events resulting in death, hospitalization, or life-threatening status. Not Officially Documented
Population-Specific Risks Safety information specific to vulnerable groups (e.g., pediatric, elderly, or pregnant patients). Not Officially Documented

All officially reviewed medicines are required to have their safety data structured by regulatory bodies to isolate clinically significant risks and provide context regarding the likelihood of less serious events. Events are designated as Serious Adverse Reactions to emphasize those that meet formal criteria, such as causing persistent incapacity or requiring intervention to prevent permanent damage. The organization by System-Organ Class provides a systemic view of the medicine’s overall biological impact, as defined by pharmacovigilance standards.

Overdose and Emergency Response

Overdose and When to Seek Help

Acetaminophen overdose is defined by the potential for severe, life-threatening liver damage (hepatotoxicity) that can progress to acute liver failure and death. The most critical aspect of an overdose is the significant delay in symptom onset.

Initial symptoms are often non-specific or absent and may include mild signs such as nausea, vomiting, loss of appetite, and general abdominal discomfort. Even in cases of severe toxicity, these early, mild symptoms may not appear for up to 24 to 48 hours following ingestion.

Accidental overdose is a primary risk noted in regulatory labeling, often resulting from taking too much of a single product or concurrently using multiple products that contain acetaminophen. This factor emphasizes the need for vigilance when combining medications.

Overdose Risk & Presentation Action Required
Delayed, Severe Liver Damage Seek immediate medical attention.
Initial Symptoms Absent/Mild Seek immediate medical attention regardless of how the person feels.
Time-Critical Intervention Antidote treatment is most effective when administered within the first 8 hours post-ingestion.

Urgent Action Statement: Immediate medical attention is required for any suspected overdose. Because severe liver damage is delayed and irreversible, you must call a poison control center or emergency services right away, even if the individual appears completely well.

Therapeutic Uses of Sha Di

Sha Di is generally applied in addressing symptom clusters that interfere with daily functioning, commonly used across conditions presenting with acute bacterial manifestations of the upper and lower respiratory tract, including conditions like pneumonia, bronchitis, sinusitis, and pharyngitis. The medication is also used for managing infections of the skin and throat and is applied in addressing H. pylori in the context of duodenal ulcers. The medicine is commonly used to help with symptoms related to systemic imbalance, such as a persistent cough, chest congestion, and the presence of fever.


Quick Fact: Support for Acute Symptom Manifestations The medication is considered relevant for use when acute bacterial manifestations affect the airways or skin, assisting with maintaining functional stability during symptomatic episodes.


This medication is relevant for managing symptom clusters that may become intense or disruptive, commonly used across conditions presenting with localized bacterial invasion of the skin and soft tissues (e.g., cellulitis) and conditions like acute otitis media (middle ear infection). It provides support that helps ease the overall symptom burden. Furthermore, Sha Di is considered a relevant therapeutic option for patients with penicillin allergies and may be part of symptomatic management, applied when additional anti-infection support is needed to address acute or specialized infections like Mycobacterium avium Complex (MAC).

“This therapeutic approach is primarily relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden from bacterial causes.”

Regulatory References

  1. NIH MedlinePlus overview of Clarithromycin

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility

Sha Di (Clarithromycin) eligibility is strictly defined by regulatory criteria regarding patient health status and age.

Absolute Contraindications

Use is strictly prohibited for patients with known macrolide hypersensitivity or a history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use. The medicine is also contraindicated in patients with known QT prolongation, pre-existing ventricular cardiac arrhythmias (including Torsades de Pointes), or uncorrected hypokalaemia/hypomagnesaemia. It must not be used in patients with severe hepatic failure combined with renal impairment.

Age and Organ Function Restrictions

Clarithromycin tablets are not recommended for children younger than 12 years; the oral suspension is the approved formulation for children 6 months to 12 years. Safety is not established for infants under six months of age. Use requires caution in patients with impaired hepatic function or pre-existing coronary artery disease. Patients with severe renal impairment (creatinine clearance <30 mL/min) require a formal restriction of use.

Pregnancy and Lactation

Clarithromycin is not recommended for use in pregnant women unless no appropriate alternative is available. Since the medicine passes into breast milk, regulatory labeling advises a decision to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

The interaction profile for Sha Di (Clarithromycin) is primarily defined by its regulatory classification as a strong inhibitor of the CYP3A4 enzyme and documented inhibition of drug transporters, including P-glycoprotein. This action significantly raises the plasma concentrations of many co-administered medicines that are substrates for these pathways.

Several combinations are officially contraindicated. These include the anti-arrhythmics Pimozide, Cisapride, Astemizole, and Terfenadine due to the severe risk of cardiac events like QT prolongation. Ergot Alkaloids (e.g., Ergotamine) are also contraindicated due to the risk of acute ergot toxicity, such as vasospasm. The statins Lovastatin and Simvastatin are prohibited, and therapy with these medicines must be suspended during the course of Clarithromycin treatment due to the increased risk of myopathy, including rhabdomyolysis.

Clarithromycin also increases the exposure of agents like Digoxin, Theophylline, and certain immunosuppressants and Calcium Channel Blockers, necessitating close monitoring. A separate pharmacodynamic risk includes the additive potential for QT prolongation with other agents and increased risk of hypoglycemia when co-administered with insulin or oral hypoglycemic agents. Furthermore, the combination with Colchicine is strictly contraindicated for patients with renal or hepatic impairment. The immediate-release formulation may be administered without regard to food.

Mechanism of Action

How Sha Di Works — Mechanism of Action

Modulating Inflammation and Oxidative Stress

The mechanism of action primarily involves a dual molecular interaction. Active components function as antioxidants by scavenging reactive oxygen species (ROS) and directly inhibiting key enzymes within the inflammatory signaling pathways. This activity serves to modulate systemic and cellular stress, influencing molecular processes associated with tissue irritation.

Supporting Cellular and Tissue Integrity

Sha Di components interact with and modulate intracellular signaling proteins, such as cell cycle regulators, to influence factors governing cell membrane stability against chemical and oxidative damage. This mechanism is relevant for processes involving the integrity of tissue surfaces, particularly epithelial and mucosal linings.

Regulating Secretory and Fluid Balance

The drug acts to influence the autonomic signals that govern glandular function, thereby influencing the production of glandular secretions. By adjusting activity in these regulatory pathways, the mechanism modulates factors associated with homeostatic balance and the function of secretory systems.

Dosage and Administration Information

Sha Di, containing Clarithromycin, is administered through the oral route, available as immediate-release tablets, extended-release tablets, and granules for suspension. An Intravenous (IV) route is also used, typically reserved for short-term use in hospitalized patients with severe infections. The dosing regimen determines the usage frequency: standard immediate-release forms are generally taken twice daily (every 12 hours), while the extended-release tablet is used once daily (every 24 hours).

Standard adult dosing ranges from 250 mg to 500 mg every 12 hours, depending on the indication. Pediatric patients (6 months to 12 years) are typically administered the suspension at a weight-based dose of 7.5 mg/kg twice daily. The treatment course usually extends from 6 to 14 days, though treatment for specific infections, such as streptococcal, is required to last for at least 10 days to complete the course.

Administration requires adherence to form-specific conditions. Extended-release tablets must be swallowed whole and not crushed or chewed; they are required to be taken with food. Immediate-release forms may be taken with or without food. Adults with significantly impaired kidney function (CrCl < 30 mL/min) have the standard dose reduced by one-half. If a dose is missed, standard practice involves skipping the missed dose if it is near the time for the next dose, and never taking a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sha Di (Clarithromycin)


Evidence for Use in Respiratory Tract and Skin Infections

Research exploring the clinical evaluation of Sha Di (Clarithromycin) has generally involved comparative studies called Randomized Controlled Trials (RCTs). These trials were used in research exploring how symptoms change over time in adults and adolescents with conditions commonly associated with bacterial respiratory infections (such as pneumonia and bronchitis). Studies also included younger populations where the medicine was applied in studies examining patient-reported experiences related to ear infections (acute otitis media). These trials monitored outcomes related to systemic or functional imbalance, such as measurements of fever and changes in respiratory symptom scores. Studies reported that measurements taken after the use of Clarithromycin were observed to be similar to measurements taken following other standard antibiotics in the trials.

Evidence for Use in Specialized Infections

Sha Di was evaluated in trials using combination therapy for specialized conditions like Helicobacter pylori (H. pylori) infection, which is associated with duodenal ulcers, and Mycobacterium avium Complex (MAC) infection. These studies monitored microbiological endpoints, tracking the rate at which the full combination regimen eradicated the bacteria or reduced the mycobacterial load. Data show patterns related to eradication, but research is ongoing as bacterial Clarithromycin resistance continues to grow globally. The contribution of Clarithromycin alone to the overall observed effect is difficult to quantify when studied only within combination regimens.

Long-Term Research and Follow-up Findings

Research has explored outcomes that extend significantly beyond the treatment period, notably in one large, long-term follow-up trial of adults with stable Coronary Heart Disease (CAD). This trial tracked outcomes such as all-cause mortality and cardiovascular events over a follow-up period extending up to 10 years. The long-term follow-up described patterns showing an observed difference in mortality rates between the group that received Clarithromycin and the group that received placebo, which was subsequently reviewed by regulatory bodies. Conversely, several subsequent observational studies reported mixed or inconsistent patterns when tracking cardiovascular events in similarly studied populations.

Key Studies & References

  1. Clarithromycin: overview and its current clinical utility in the treatment of respiratory tract infections
  2. What are the latest guideline recommendations for the treatment of Helicobacter pylori infection in the U.S.?
  3. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs - Clinical Info.HIV.gov Guidelines

Frequently Asked Questions (FAQ)

Common questions about Sha Di (FAQ)

Q: What is Sha Di used for, in simple terms?

A: Sha Di is classified as a macrolide antibiotic. According to official prescribing information, it is used in the treatment of various bacterial infections across the body, such as those affecting the respiratory tract and skin. The medicine's action involves either killing susceptible bacteria or inhibiting their growth and reproduction.

Q: Is Sha Di the same type of medicine as [similar common drug name]?

A: Sha Di contains the active ingredient Clarithromycin, which is part of the macrolide antibiotic class of medicines. This class includes other commonly known antibiotics, such as Erythromycin and Azithromycin. The classification is based on the compound's chemical structure and its defined mechanism of action against bacteria.

Q: How quickly does Sha Di start to work after taking it?

A: Official patient guidance indicates that for most common infections, improvement is typically observed within a few days of beginning treatment with Sha Di. For certain conditions, such as some skin infections, the time until improvement is noticed may extend up to about seven days. Regulatory guidance suggests completing the full prescribed course.

Q: Are there any common foods or drinks that should be avoided when using Sha Di?

A: The official product information primarily provides instructions on the administration of the dose (with or without food), but does not generally list specific common foods that are prohibited. Regulatory information indicates that patients often check with a healthcare provider regarding potential interactions, particularly with alcohol.

Q: Can Sha Di cause tiredness or make you feel dizzy?

A: Yes, regulatory safety documents include dizziness and fatigue (unusual tiredness) as possible reported side effects. These effects are part of the medicine's defined safety profile. Information regarding severe or persistent side effects is generally included in patient information leaflets.

Q: What are the most common side effects people report with Sha Di?

A: The side effects most frequently reported in official documents are often related to the digestive system. These include abdominal pain, diarrhea, nausea, vomiting, and a change in how things taste (dysgeusia).

Q: Can I take Sha Di if I am already taking over-the-counter pain relievers?

A: While the official prescribing information includes warnings for many prescription medicines, it may not list every single over-the-counter (OTC) product. Because Sha Di and certain OTC pain relievers (like Acetaminophen) carry warnings about potential liver effects, regulatory documents suggest that patients often check with a doctor or pharmacist about combining medications.

Q: Does Sha Di interact with common supplements like vitamins or herbal products?

A: Yes, official guidance explicitly notes that certain herbal products, such as St. John’s Wort, may interact with Sha Di. As supplements are often not tested for drug interactions, official information indicates that patients typically consult a doctor or pharmacist before taking supplements or herbal remedies while using this medicine.

Q: Is it normal to feel a change in appetite while using Sha Di?

A: Yes, regulatory safety information includes loss of appetite (anorexia) as a possible documented systemic effect. This is one of the adverse reactions that have been reported in association with the medicine.

Q: Do older adults use Sha Di differently than younger people?

A: Regulatory warnings indicate that elderly patients may have an increased susceptibility to certain drug-associated effects, particularly those related to the heart’s electrical activity (QT interval prolongation). This population may be subject to closer monitoring, according to regulatory warnings.

Q: Can Sha Di affect my ability to drive or operate machinery?

A: Official information warns that Sha Di may cause side effects such as dizziness, confusion, or disorientation. Regulatory guidance includes warnings about driving and operating heavy machinery due to these potential side effects.

Q: What is the proper way to stop using Sha Di, if needed?

A: Regulatory guidance emphasizes that the medicine is prescribed to be taken for the full course of treatment to ensure the infection is completely cleared. Interrupting the course earlier, even if a patient feels better, may increase the likelihood that the infection is not fully resolved.

Q: Does Sha Di have a known interaction with alcohol?

A: While the official prescribing information may not list alcohol as a strict contraindication, general patient guidance advises caution when combining alcohol with antibiotics. Alcohol can potentially worsen certain side effects associated with Sha Di, and official guidance suggests that patients often consult a healthcare professional about alcohol use.

Q: Can Sha Di interfere with birth control pills?

A: Official information indicates that Sha Di generally does not stop contraceptive pills from working. However, if the medicine leads to severe symptoms like vomiting or severe diarrhea that lasts for more than 24 hours, the effectiveness of oral contraception may be reduced. Information regarding the need for backup contraception is included in the official patient information.

Q: Does Sha Di have any effect on blood pressure?

A: Official documents link Sha Di to the risk of QT interval prolongation, which involves a change in the heart's electrical activity. Regulatory warnings mention informing healthcare providers about a history of heart rhythm problems due to this potential cardiac risk.

Q: What should I do if I suspect a serious side effect from Sha Di?

A: Official information describes symptoms that warrant the immediate discontinuation of the medicine and seeking emergency medical help. This applies to signs of a severe allergic reaction (e.g., swelling, breathing trouble) or serious skin or liver reactions.

Q: Can Sha Di cause or worsen headaches?

A: Yes, regulatory patient guidance confirms that headache is listed as one of the commonly reported side effects associated with this medicine.

Q: How long after starting Sha Di should I expect to see the full effect?

A: While patients typically begin to feel better within a few days, the official full therapeutic effect is achieved by completing the entire course of treatment. The duration of the course is defined to ensure the infection is fully addressed.

Q: What is the risk of having an allergic reaction to Sha Di?

A: Regulatory documents confirm that severe acute allergic reactions, including anaphylaxis, have been reported in association with the medicine. Official safety information describes the characteristics of patients for whom the medicine is not generally used due to allergy risk, such as those allergic to other macrolide antibiotics.

Q: Can Sha Di be used during pregnancy or breastfeeding, based on official advice?

A: Official guidance advises that use during pregnancy is generally not recommended unless the potential benefit is judged to outweigh the potential risk. Regarding breastfeeding, use is generally considered acceptable, but official patient information suggests monitoring the infant for potential gastrointestinal effects.

Q: Are there warnings about taking Sha Di with other prescriptions for anxiety or sleep?

A: Yes, official drug interaction information specifically notes interactions with certain prescriptions used for anxiety or sleeplessness. For example, the drug can interact with Midazolam, leading to increased exposure of that medicine in the body.

Q: If I have a food allergy, is Sha Di safe to use?

A: Official warnings note that the medicine is generally not used if a patient is allergic to Sha Di or any of the inactive ingredients (excipients) in the specific formulation. Patients often check the official product label for the full list of ingredients to manage allergy risks.

Q: Can Sha Di affect the results of lab tests?

A: Official medical information notes that healthcare providers may order specific laboratory tests while a patient is using Sha Di. This is typically done to monitor the body's response to the medicine and check for potential changes in systemic function.

How should Sha Di be stored and disposed of?

Official Storage and Disposal Requirements

Dosage Form Required Storage Conditions
Tablets / Dry Granules Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Protect the dry granules from light and moisture and keep the container tightly closed.
Prepared Suspension Store at room temperature, 15 C to 30 C (59 F to 86 F). Do not refrigerate and do not freeze.

All forms of the medicine must be stored in the original container and kept out of the sight and reach of children.

Disposal

Unused or expired product must not be disposed of by pouring it down a drain, flushing it down a toilet, or placing it in household trash. Patients should consult a pharmacist or local waste disposal service for guidance. Utilizing medication take-back programs is the regulatory preferred method for discarding unused medicine. The prepared oral suspension must be discarded after 14 days.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sha Di found in:

A-Z Index: